1-3 of 3
Elisa Brighenti
Close
Sort by
Journal Articles

The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Ilaria Iacobucci, PhD, Federica Cattina, MD, Silvia Pomella, Annalisa Lonetti, Enrico Derenzini, MD, Elisa Brighenti, Anna Ferrari, Cristina Papayannidis, Maria Vittoria Verga Falzacappa, Viviana Guadagnuolo, Michela Aluigi, PhD, Emanuela Ottaviani, Serena Formica, Maria Chiara Abbenante, Simona Soverini, Domenico Russo, Fabrizio Pane, Pier Guiseppe Pellicci, Michele Baccarani, MD, Giovanni Martinelli
Journal: Blood
Blood (2011) 118 (21): 76.
https://doi.org/10.1182/blood.V118.21.76.76
Published: 2011
Journal Articles

The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma

Enrico Derenzini, MD, Manuela Lemoine, PhD, Elisa Brighenti, PhD, Richard Eric Davis, MD, Pier Luigi Zinzani, MD, Anas Younes, MD
Journal: Blood
Blood (2011) 118 (21): 2731.
https://doi.org/10.1182/blood.V118.21.2731.2731
Published: 2011
Journal Articles

The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma

Enrico Derenzini, MD, Ilaria Iacobucci, PhD, Elisa Brighenti, PhD, Federica Cattina, MD, Richard Eric Davis, MD, Stefano Pileri, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2011) 118 (21): 2732.
https://doi.org/10.1182/blood.V118.21.2732.2732
Published: 2011